Cargando…

Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents

In this review, we examine the pharmacokinetics and clinically relevant drug interactions of the newer generation direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C, specifically sofosbuvir/velpatasvir (Epclusa(®)), sofosbuvir/velpatasvir/voxilaprevir (Vosevi(®)), glecaprevir/p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Jenny, Wright, Robert C., Partovi, Nilu, Yoshida, Eric M., Hussaini, Trana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Inc. 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7562806/ https://www.ncbi.nlm.nih.gov/pubmed/33083256 http://dx.doi.org/10.14218/JCTH.2020.00034

Ejemplares similares

Early Persistent Progressive Acute Kidney Injury and Graft Failure Post Liver Transplantation
por: Hussaini, Trana, et al.
Publicado: (2019)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
por: John, Jason J., et al.
Publicado: (2021)

Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents
por: Xiao, Fei, et al.
Publicado: (2014)

Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
por: Toshikuni, Nobuyuki
Publicado: (2017)

Direct-acting antiviral agents against hepatitis C virus and lipid metabolism
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
por: Ghweil, Ali A, et al.
Publicado: (2019)

Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C
por: Gao, Lu-Hua, et al.
Publicado: (2021)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea
por: Kim, Kyung-Ah, et al.
Publicado: (2023)

Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease
por: Maruyama, Anna, et al.
Publicado: (2016)

Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates
por: Gadiparthi, Chiranjeevi, et al.
Publicado: (2018)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
por: Zanaga, L.P., et al.
Publicado: (2016)

Hypozincemia in Chronic Hepatitis C Is Improved with Viral Clearance by Direct-acting Antiviral Agents
por: Shirahashi, Ryosaku, et al.
Publicado: (2021)

Factors Associated with the Refusal of Direct-Acting Antiviral Agents for the Treatment of Hepatitis C in Taiwan
por: Chang, Li-Jen, et al.
Publicado: (2022)

The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection
por: Dawood, Reham M, et al.
Publicado: (2022)

Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?
por: Nemteanu, Roxana, et al.
Publicado: (2023)

Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents
por: Cholankeril, George, et al.
Publicado: (2017)

Ursodeoxycholic Acid in Treatment of Non-cholestatic Liver Diseases: A Systematic Review
por: Reardon, Jillian, et al.
Publicado: (2016)

Next-generation direct-acting influenza therapeutics
por: Toots, Mart, et al.
Publicado: (2020)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal, Sanaa M
Publicado: (2014)

SASLT Position Statement on the Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection
por: Alghamdi, Abdullah S., et al.
Publicado: (2015)

Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents
por: Westermann, Claudia, et al.
Publicado: (2018)

Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan
por: Khaliq, Saba, et al.
Publicado: (2018)

Curative Effects for B-Cell Lymphoma Accomplished by Direct-Acting Antiviral Agents of Hepatitis C
por: Hattori, Nobuhiro, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany
por: Runge, Melanie, et al.
Publicado: (2020)

Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents
por: Westermann, Claudia, et al.
Publicado: (2021)

Hepatitis C Screening and Treatment Program in Hungarian Prisons in the Era of Direct Acting Antiviral Agents
por: Werling, Klára, et al.
Publicado: (2022)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus
por: Liu, Dandan, et al.
Publicado: (2023)

Reduced work absenteeism in patients with hepatitis C treated with second‐generation direct‐acting antivirals
por: Lindgren, Peter, et al.
Publicado: (2020)

Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review
por: Hussaini, Trana
Publicado: (2016)

Resolution of refractory hepatic hydrothorax in patients with hepatitis C virus cirrhosis after treatment with direct-acting antiviral agents
por: Hussein, Maged H., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0t8j1o2h0j9c6f9ed9cltuq3in